Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Rovin Capital UT ADV

Rovin Capital UT ADV cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 4,969 shares of the medical equipment provider’s stock after selling 1,457 shares during the period. Rovin Capital UT ADV’s holdings in Zimmer Biomet were worth $525,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Acadian Asset Management LLC increased its stake in Zimmer Biomet by 600.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,572 shares of the medical equipment provider’s stock worth $386,000 after buying an additional 3,062 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Zimmer Biomet by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,810,770 shares of the medical equipment provider’s stock valued at $196,523,000 after acquiring an additional 154,447 shares in the last quarter. Citizens Financial Group Inc. RI lifted its stake in shares of Zimmer Biomet by 60.4% in the second quarter. Citizens Financial Group Inc. RI now owns 2,642 shares of the medical equipment provider’s stock worth $287,000 after acquiring an additional 995 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Zimmer Biomet in the second quarter valued at about $19,633,000. Finally, Edgestream Partners L.P. acquired a new stake in Zimmer Biomet during the 2nd quarter valued at approximately $1,674,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the subject of several research analyst reports. Evercore ISI reduced their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Wells Fargo & Company lifted their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Royal Bank of Canada lifted their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Finally, Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $123.33.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $106.34 on Thursday. The firm has a 50-day moving average price of $107.88 and a 200 day moving average price of $107.97. The firm has a market capitalization of $21.17 billion, a PE ratio of 20.22, a P/E/G ratio of 1.79 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter in the previous year, the company earned $1.65 earnings per share. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.